Odyssey Therapeutics and Mobia Medical File for US Public Listings

The US IPO pipeline is expanding as Odyssey Therapeutics Inc. and Mobia Medical Inc. officially filed for public listings with the Securities and Exchange Commission. The move reflects a growing trend of healthcare companies seeking to transition to public markets to fund further innovation. This activity comes amid a period of robust investor demand for biotechnology and healthcare stocks. As market conditions stabilize, firms are increasingly looking to capitalize on this appetite to raise the necessary capital for clinical trials and product scaling. Odyssey Therapeutics is specializing in the development of treatments for patients suffering from inflammatory and autoimmune diseases. Joining them in the filing process is the Austin-based Mobia Medical Inc., which operates within the medical device sector. While specific offering sizes and pricing have not yet been disclosed, these filings suggest a broader recovery in the biotech equity markets. The entry of these firms serves as a signal of confidence in the sector's ability to attract public capital after a period of volatility.